期刊文献+

预防性人乳头瘤病毒疫苗Gardasil和Cervarix的临床应用 被引量:1

Clinical application of human papillomavirus vaccines Gardasil and Cervarix
下载PDF
导出
摘要 人乳头瘤病毒(human papillomavirus,HPV)感染可能导致宫颈癌、肛门生殖器癌和口咽癌。目前,已得到世界范围内应用的HPV疫苗主要有二价疫苗Cervarix和四价疫苗Gardasil。高免疫原性、安全、有效的HPV疫苗可预防和控制多个部位,包括宫颈、外阴、阴道、肛门和阴茎等的HPV感染相关疾病。上市前、后的研究都显示,Cervarix和Gardasil具有很高的安全性。但其推广应用也面临一些问题。 Oncogenic human papillomavirus(HPV) infection is the main cause of cervical cancer and anogenital and oropharyngeal cancers. A bivalent vaccine Cervarix and a quadrivalent vaccine Gardasil have been applying in vaccination programs around the world. Some highly immunogenic, safe, and effective vaccines are now available to control HPV-related diseases with proven efficacy against diseases at many anatomical sites, including the cervix, vulva, vagina, anus, and penis ones. The data from pre-licensure and post-licensure studies have showed that both Cervarix and Gardasil are vaccines with high safety. However, there are some barriers in the promotion and application of HPV vaccination.
出处 《上海医药》 CAS 2016年第11期8-11,24,共5页 Shanghai Medical & Pharmaceutical Journal
关键词 人乳头瘤病毒 疫苗 临床应用 human papillomavirus vaccine clinical application
  • 相关文献

参考文献38

  • 1Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP) [J]. MMWR Recomm Rep, 2014, 63(RR-05): 1-30.
  • 2Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of- principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine [J]. J Natl Cancer Inst, 2011, 103(19): 1444-1451.
  • 3Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial [J]. Cancer Prev Res (Phila), 2013, 6(11): 1242-1250.
  • 4Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial [J]. JAMA, 2013, 309(17): 1793-1802.
  • 5Lazcano-Ponce E, Stanley M, Mufioz N, et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months [J]. Vaccine, 2014, 32(6): 725-732.
  • 6Human papillomavirus vaccines: WHO position paper, October 2014 [J]. Wkly Epidemiol Rec, 2014, 89(43): 465- 491.
  • 7Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 -- conclusions and recommendations [J]. Wkly Epidemiol Rec, 2014, 89(21): 221-236.
  • 8Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction -- the first five years [J]. Vaccine, 2012, 30(Suppl 5): F139-F148.
  • 9Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis [J]. Lancet Infect Dis, 2015, 15(5): 565-580.
  • 10Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years -- United States, 2014 [J]. MMWR Morb Mortal Wkly Rep, 2015, 64(29): 784-792.

同被引文献10

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部